Veloxis to Host Conference Call Following Release of 2018 Annual Report

Hørsholm, DENMARK


 

Investor News no. 01/2019

To: NASDAQ Copenhagen A/S                                                  

Copenhagen, Denmark, 26 February 2019


Veloxis to Host Conference Call Following Release of 2018 Annual Report


As previously announced, Veloxis Pharmaceuticals A/S (NASDAQ: VELO) will release its 2018 Annual Report on Wednesday, February 27, 2019.  In connection with the release, Veloxis’s Executive Management will host a conference call to discuss the 2018 financial results on Thursday, February 28, 2019 at 4:00 p.m. CET (Denmark); 3:00 p.m. GST (London); and 10:00 a.m. EST (New York).


To access the live conference call, please dial one of the following numbers:

+45 32 72 75 18 (Denmark)

+44 (0) 203 009 5710 (UK)

+1 917 720 0178 (USA)

Confirmation Code: 2466359


Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com.


For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR® (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

Attachment


Attachments

2019.02.26 Investor News 01 - Veloxis to Host Conference Call re Annual Report 2018